• Explore /
  • Poster
  • / frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.

frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma.

Abstract Video & Slides Poster

Authors

Umberto Vitolo

Umberto Vitolo

Candiolo Cancer Institute, Torino, Italy

Umberto Vitolo , Grzegorz S. Nowakowski , John M. Burke , Christopher P. Fox , Marek Trneny , Annalisa Chiappella , Maeve Waldron-Lynch , Nira Hadar , Alok Pachori , Georg Lenz

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04824092

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS7590)

DOI

10.1200/JCO.2022.40.16_suppl.TPS7590

Abstract #

TPS7590

Poster Bd #

236b

Abstract Disclosures

Similar Posters

First Author: David Belada

First Author: Grzegorz S. Nowakowski

First Author: Bei Hu

First Author: Herve Tilly